Drug Approval | August 06, 2023
Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma
The inspection closed with zero observations and a classification of No Action Indicated
The inspection closed with zero observations and a classification of No Action Indicated
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Subscribe To Our Newsletter & Stay Updated
